Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Continuous glucose monitors may reveal hidden heart risk patterns in adults without diabetes (opens in a new tab)

medicalxpress.com · 2026-09-17

Short answerEvidenceSource

Short answer

Supported

Supported.

The story matches what the study reports.

  • 4 supported

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Supported

Every claim holds up. All four claims match what the study reports.

  • 4 supported
Open claim evidence
3

The source study

Beyond Traditional Glycemic Measures: CGM Glycemic Profiles Reveal Associations With Cardiometabolic Risk in Individuals Without Diabetes

Diabetes Care · 2026
Open source record (opens in a new tab)
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4SupportedResearchers at Boston University Chobanian & Avedisian School of Medicine found that glucose patterns captured by continuous glucose monitoring among adults without diabetes are related to markers of cardiometabolic risk.View evidenceHide evidence

Why this verdict

The abstract-level profile supports an associational claim: in adults without diabetes, CGM-derived glycemic measures/profiles were associated with PREVENT estimated 10-year CVD risk and individual cardiometabolic risk factors. The story frames this as 'related to' risk markers rather than causal.

1

Study evidence

Higher time in glucose >140 mg/dL (per 1 SD = 15.4%) was associated with higher estimated 10-year CVD risk.2% higher 10-year PREVENT CVD risk estimate per 1 SD higher time >140 mg/dL

“We included 1,356 participants without prevalent diabetes or CVD from the Framingham Heart Study, who wore a blinded Dexcom G6 Pro CGM for up to 10 days.”
2

Study evidence

Higher short-term CGM glycemia (percent time >140 mg/dL) was positively associated with higher estimated 10-year CVD risk and higher odds of hypertension and dyslipidemia, independent of FPG.Per 1 SD (15.4%) higher percent time >140 mg/dL: +2% PREVENT 10-year CVD risk estimate; 21–26% higher odds of hypertension and dyslipidemia

“CGM glycemic profiles were characterized using 1) binary classification of glycemic burden and variability and 2) unsupervised clustering of CGM measures.”
Claim 2 of 4SupportedThe researchers analyzed continuous glucose monitoring data from approximately 1,300 participants in the Framingham Heart Study who did not have diabetes or cardiovascular disease.View evidenceHide evidence

As statedapproximately 1,300 participants

Why this verdict

The paper profile reports 1,356 Framingham Heart Study participants without prevalent diabetes or CVD who wore blinded Dexcom G6 Pro CGM for up to 10 days. The story's 'approximately 1,300' and exclusion of diabetes/CVD are consistent with the abstract evidence.

1

Study evidence

Higher time in glucose >140 mg/dL (per 1 SD = 15.4%) was associated with higher estimated 10-year CVD risk.2% higher 10-year PREVENT CVD risk estimate per 1 SD higher time >140 mg/dL

“We included 1,356 participants without prevalent diabetes or CVD from the Framingham Heart Study, who wore a blinded Dexcom G6 Pro CGM for up to 10 days.”
2

Study evidence

Higher short-term CGM glycemia (percent time >140 mg/dL) was positively associated with higher estimated 10-year CVD risk and higher odds of hypertension and dyslipidemia, independent of FPG.Per 1 SD (15.4%) higher percent time >140 mg/dL: +2% PREVENT 10-year CVD risk estimate; 21–26% higher odds of hypertension and dyslipidemia

“CGM glycemic profiles were characterized using 1) binary classification of glycemic burden and variability and 2) unsupervised clustering of CGM measures.”
Claim 3 of 4SupportedHigher average glucose and a higher percentage of time blood sugar exceeded 140 mg/dL were associated with higher risks of hypertension or high cholesterol.View evidenceHide evidence

Why this verdict

The paper profile reports positive associations between higher CGM measures and adverse cardiometabolic risk factors. It specifically reports that 1 SD higher time above 140 mg/dL was associated with 21–26% higher odds of hypertension and dyslipidemia after FPG adjustment. The story's wording is broadly supported, though the paper evidence is cross-sectional odds/prevalent risk-factor status rather than incident hypertension or future high cholesterol.

1

Study evidence

Higher time in glucose >140 mg/dL (per 1 SD = 15.4%) was associated with higher estimated 10-year CVD risk.2% higher 10-year PREVENT CVD risk estimate per 1 SD higher time >140 mg/dL

“We included 1,356 participants without prevalent diabetes or CVD from the Framingham Heart Study, who wore a blinded Dexcom G6 Pro CGM for up to 10 days.”
2

Study evidence

Higher short-term CGM glycemia (percent time >140 mg/dL) was positively associated with higher estimated 10-year CVD risk and higher odds of hypertension and dyslipidemia, independent of FPG.Per 1 SD (15.4%) higher percent time >140 mg/dL: +2% PREVENT 10-year CVD risk estimate; 21–26% higher odds of hypertension and dyslipidemia

“CGM glycemic profiles were characterized using 1) binary classification of glycemic burden and variability and 2) unsupervised clustering of CGM measures.”
Claim 4 of 4SupportedThe article says the findings could ultimately inform future approaches to identifying individuals at greater risk for poor cardiometabolic health, but additional studies are needed.View evidenceHide evidence

Why this verdict

The paper profile says CGM-derived metrics/profiles may provide additional insights into cardiometabolic risk beyond FPG/HbA1c, and the story hedges this as a possible future use while noting more studies are needed. This is consistent with the abstract-level evidence and limitations, so long as it is read as speculative rather than a present clinical recommendation.

1

Study evidence

Higher time in glucose >140 mg/dL (per 1 SD = 15.4%) was associated with higher estimated 10-year CVD risk.2% higher 10-year PREVENT CVD risk estimate per 1 SD higher time >140 mg/dL

“We included 1,356 participants without prevalent diabetes or CVD from the Framingham Heart Study, who wore a blinded Dexcom G6 Pro CGM for up to 10 days.”
2

Study evidence

Higher short-term CGM glycemia (percent time >140 mg/dL) was positively associated with higher estimated 10-year CVD risk and higher odds of hypertension and dyslipidemia, independent of FPG.Per 1 SD (15.4%) higher percent time >140 mg/dL: +2% PREVENT 10-year CVD risk estimate; 21–26% higher odds of hypertension and dyslipidemia

“CGM glycemic profiles were characterized using 1) binary classification of glycemic burden and variability and 2) unsupervised clustering of CGM measures.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The paper also derived CGM glycemic profiles using rule-based burden/variability categories and unsupervised clustering, and found partial discordance with FPG/HbA1c categories.

    The story mentions hidden dysglycemia and static FPG/HbA1c snapshots, but it does not materially describe the profile-construction analyses, unsupervised clustering, or the reported discordance ranges with traditional glycemic status.

    From observational cross-sectional profiling and association

  • Key limitation: observational cross-sectional design precludes causal inference and temporality.

    The story uses mostly associational language and says additional studies are needed, but the supplied caveats do not explicitly acknowledge that the cross-sectional design cannot establish temporality or causation.

    From Cross-sectional observational analysis (community cohort); observational cross-sectional profiling and association

  • Key limitation: PREVENT is an estimated 10-year CVD risk score, not observed incident cardiovascular events.

    The story discusses cardiometabolic and future cardiovascular risk but does not appear to clarify that the CVD outcome in the paper was an estimated risk calculation rather than observed future CVD events.

    From Cross-sectional observational analysis (community cohort); observational cross-sectional profiling and association

  • Key limitation: the sample was predominantly non-Hispanic White, which may limit generalizability.

    The supplied story caveats do not mention the cohort's demographic composition or generalizability limitation.

    From Cross-sectional observational analysis (community cohort); observational cross-sectional profiling and association

  • Key limitation: CGM monitoring lasted up to 10 days and may not capture longer-term glycemic patterns.

    The story does not mention the short CGM monitoring period or the possibility that brief monitoring may not represent habitual long-term glycemia.

    From Cross-sectional observational analysis (community cohort); observational cross-sectional profiling and association

3 things the story did carry across
  • Cross-sectional Framingham Heart Study sample of 1,356 adults without diabetes or prevalent CVD wearing blinded CGM up to 10 days.
  • CGM-derived glycemic measures were associated with estimated 10-year CVD risk and individual cardiometabolic risk factors in multivariable-adjusted models.
  • Time above 140 mg/dL was specifically associated with higher estimated CVD risk and higher odds of hypertension and dyslipidemia after adjustment including fasting plasma glucose.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoAssess whether CGM-derived glycemic measures are associated with 10-year estimated CVD risk and individual cardiometabolic risk factors (CMRFs) among adults without diabetes.Cross-sectional observational analysis (community cohort)Expand

In plain English

Cross-sectional analysis of 1,356 Framingham Heart Study participants without diabetes or CVD who wore a blinded Dexcom G6 Pro CGM for up to 10 days. Multivariable-adjusted linear and logistic regression models examined associations of CGM-derived measures and unsupervised CGM glycemic profiles with PREVENT 10-year CVD risk estimates and individual cardiometabolic risk factors (CMRFs), with select models adjusted for fasting plasma glucose (FPG). The study reports positive associations between higher CGM dysglycemia and both higher estimated 10-year CVD risk and greater odds of hypertension and dyslipidemia, and notes that CGM-derived dysglycemia profiles are not fully concordant with traditional glycemic categories (FPG/HbA1c).

Key findings

  • Higher time in glucose >140 mg/dL (per 1 SD = 15.4%) was associated with higher estimated 10-year CVD risk.2% higher 10-year PREVENT CVD risk estimate per 1 SD higher time >140 mg/dL
  • Higher time in glucose >140 mg/dL (per 1 SD = 15.4%) was associated with greater odds of hypertension and dyslipidemia.21–26% higher odds of hypertension and dyslipidemia per 1 SD higher time >140 mg/dL
“We included 1,356 participants without prevalent diabetes or CVD from the Framingham Heart Study, who wore a blinded Dexcom G6 Pro CGM for up to 10 days.”
What this piece can’t prove
  • Cross-sectional observational design; cannot infer causality or temporal relationships.
  • Study sample largely non-Hispanic White (92.6%), which may limit generalizability to more diverse populations.
  • CGM monitoring was limited to up to 10 days; short-term monitoring may not capture longer-term glycemic patterns.
  • Findings are based on estimated 10-year CVD risk (PREVENT equations) rather than observed CVD events.

1 further detail could not be confirmed from the summary.

2human in vivoDerive and evaluate CGM-based glycemic profiles (rule-based burden/variability categories and unsupervised clusters) and test whether these profiles reveal risk/CMRF differences and discordance with traditional glycemic status (FPG/HbA1c).observational cross-sectional profiling and associationExpand

In plain English

In a cross-sectional analysis of 1,356 Framingham Heart Study participants without diabetes or prevalent CVD who wore a blinded Dexcom G6 Pro CGM (up to 10 days), the authors derived CGM glycemic profiles using (1) rule-based binary classifications of glycemic burden and variability and (2) unsupervised clustering of CGM features. They tested associations of CGM measures and profile membership with PREVENT 10-year CVD risk estimates and individual cardiometabolic risk factors (CMRFs), and compared profile membership with traditional glycemic categories based on fasting plasma glucose (FPG) and HbA1c. Higher CGM measures (for example, percent time >140 mg/dL) and profiles indicating greater dysglycemia were associated with higher estimated 10-year CVD risk and worse CMRFs; CGM-derived higher-dysglycemia profiles showed incomplete concordance with FPG/HbA1c-defined prediabetes.

Key findings

  • Higher short-term CGM glycemia (percent time >140 mg/dL) was positively associated with higher estimated 10-year CVD risk and higher odds of hypertension and dyslipidemia, independent of FPG.Per 1 SD (15.4%) higher percent time >140 mg/dL: +2% PREVENT 10-year CVD risk estimate; 21–26% higher odds of hypertension and dyslipidemia
  • CGM-derived glycemic profiles denoting higher dysglycemia (constructed via rule-based burden/variability categories and via unsupervised clustering) were associated with ~6–7% higher PREVENT 10-year CVD risk estimates and worse cardiometabolic risk factor profiles.Profiles representing higher dysglycemia associated with 6–7% higher PREVENT 10-year CVD risk estimates
“CGM glycemic profiles were characterized using 1) binary classification of glycemic burden and variability and 2) unsupervised clustering of CGM measures.”
What this piece can’t prove
  • Cross-sectional, observational design precludes causal inference.
  • PREVENT provides estimated 10-year CVD risk rather than observed incident CVD events.
  • CGM monitoring was limited to up to 10 days; may not reflect habitual long-term glycemic patterns.
  • Abstract lacks methodological details of the unsupervised clustering (algorithm, number of clusters, stability/validation), limiting appraisal of profile derivation.
  • Study sample is predominantly non-Hispanic White (92.6%), which may limit generalizability.
  • Potential residual confounding and incomplete specification of covariate adjustment in abstract.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Beyond Traditional Glycemic Measures: CGM Glycemic Profiles Reveal Associations With Cardiometabolic Risk in Individuals Without Diabetes

Diabetes Care · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Selected

Beyond Traditional Glycemic Measures: CGM Glycemic Profiles Reveal Associations With Cardiometabolic Risk in Individuals Without Diabetes

Diabetes Care · 2026 · Crossref

Source (opens in a new tab)
Candidate

Cardiometabolic Risk Factors in Type 2 Diabetes Persons Evaluated by Continuous Glucose Monitoring

Metabolism · 2024 · Crossref

Source (opens in a new tab)
Candidate

Faculty Opinions recommendation of The Association between Non-Invasive Hepatic Fibrosis Markers and Cardiometabolic Risk Factors in the Framingham Heart Study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · 2016 · Crossref

Source (opens in a new tab)

And 10 more candidates considered.